Photobiomodulation therapy versus sham for tibial and metatarsal bone stress injuries in military trainees: A randomized controlled trial
In brief
Photobiomodulation did not speed graduation or bone healing in trainees
In a randomized trial of 97 military trainees with bone stress injuries, photobiomodulation added to standard care did not improve time to graduation, on-time graduation, MRI healing, pain, or function compared with sham treatment. Only 37.1% graduated on time overall. The findings weigh against routine use in this setting, though the trial does not establish whether other patients might benefit.
- Journal
- Bone (Q1)
- Published
- 15 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Daniel I Rhon, Nathan A Parsons, Tina A Greenlee, Elizabeth Metzger, Steven R Hole, Nelson Hager
- PMID
- 42880535
- DOI
- 10.1016/j.bone.2026.118135
Why clinicians should know about it
- Picked for Orthopedics and Sports Medicine (top studies of the week, 22 November 2026): PBMT did not accelerate bone healing
Abstract
PURPOSE: To compare the effectiveness of active versus sham photobiomodulation therapy (PBMT) on time to graduation and bone healing in military trainees with lower extremity bone-stress injuries (BSI). MATERIALS AND METHODS: Participants were trainees at the Medical Education and Training Campus, San Antonio, Texas, with MRI-confirmed metatarsal and/or tibial BSI, enrolled between June 2023 and November 2024. All participants received standard-of-care treatment and were randomized to active or sham PBMT. The primary outcome was time to graduation (days), analyzed with a cause-specific Cox model. Secondary outcomes, assessed at four months, were on-time graduation (yes/no), the Defense and Veterans Pain Rating Scale (DVPRS), the Lower Extremity Functional Scale (LEFS), and bone healing on MRI. RESULTS: 103 participants were randomized; 97 included in the final analysis. The mean age (SD) was 23.7 (4.2) years, 52.6% female. Both extremities were affected in 47.4% of the cohort; the tibia in 70.1% and a metatarsal in 28.9% (1.0% both), with BSI severity ranging from Fredericson grade I to IVb. Only 37.1% of participants graduated on time. Time to graduation did not differ between treatment groups (Hazard Ratio for Sham versus Treatment 0.95; 95%CI 0.61 to 1.48; p = 0.83) nor did on-time graduation (Risk Ratio 0.91; 95%CI 0.54 to 1.52; p = 0.71) or BSI healing on MRI (Risk Ratio 0.89; 95%CI 0.68 to 1.16; p = 0.54). Furthermore, sex, laterality, and BSI location did not predict successful on-time graduation. Pain (mean difference [95%CI] -0.74 [-2.31 to 0.83]; p = 0.84) and function (5.95 [-7.92 to 19.81]; p = 0.89) were not significantly different at 4 months. CONCLUSION: Time to graduation, bone healing, pain intensity, and physical function did not differ significantly between trainees with BSI who received PBMT versus sham. Given the substantial resource investment, these results should be weighed when considering routine use of PBMT to manage BSIs in this setting. TRIAL REGISTRATION: ClinicalTrials.gov # NCT05843864.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.